搜尋
Ascendis Pharma A/S
ASND添加自選
243.910USD
-7.160-2.85%
收盤 07-31 16:00（美東）報價延遲15分鐘
15.12B總市值
35.15本益比TTM
關於 Ascendis Pharma A/S 公司
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S簡介
公司代碼ASND
公司名稱Ascendis Pharma A/S
上市日期Jan 28, 2015
CEOMoller Mikkelsen (Jan)
員工數量- -
證券類型Depository Receipt
年結日Jan 28
公司地址Tuborg Boulevard 12
城市HELLERUP
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Denmark
郵編2900
電話4570222244
網址https://ascendispharma.dk/
公司代碼ASND
上市日期Jan 28, 2015
CEOMoller Mikkelsen (Jan)
Ascendis Pharma A/S公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
Ms. Lotte Soenderbjerg
Ms. Lotte Soenderbjerg
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
--
--
Dr. Kennett Sprogoee, Ph.D.
Dr. Kennett Sprogoee, Ph.D.
Executive Vice President, Head of Innovation and Research
Executive Vice President, Head of Innovation and Research
--
--
Mr. Scott T. Smith
Mr. Scott T. Smith
Chief Financial Officer, Executive Vice President, Member of the Executive Board
Chief Financial Officer, Executive Vice President, Member of the Executive Board
--
--
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
常見問題
Ascendis Pharma A/S的前五大股東是誰？
Ascendis Pharma A/S的前五大股東如下：Mr. Flemming Steen Jensen
有多少機構持有Ascendis Pharma A/S(ASND)的股份？
截至2026Q1，共有582家機構持有Ascendis Pharma A/S的股份，合計持有的股份價值約為69.20M，占公司總股份的111.42% 。與2025Q4相比，機構持股有所增加，增幅為-1676383.00。
哪個業務部門對Ascendis Pharma A/S的收入貢獻最大？
在2026Q1，Commercial sale of products業務部門對Ascendis Pharma A/S的收入貢獻最大，創收683.57M，占總收入的94.92% 。